BioCentury
ARTICLE | Company News

BMS ending virology discovery, building Cambridge hub

June 26, 2015 1:23 AM UTC

Bristol-Myers Squibb Co. (NYSE:BMY) said it will discontinue drug discovery in virology as part of an ongoing R&D reorganization. The company said the change will not affect its clinical-stage and marketed virology products. BMS will cut about 100 jobs as a result of the decision.

BMS's marketed virology products include cyclopentyl guanosine nucleoside analog Baraclude entecavir to treat HBV; HIV protease inhibitor Reyataz atazanavir; and selective HCV NS5A protein inhibitor Daklinza daclatasvir and HCV NS3 protease inhibitor Sunvepra asunaprevir to treat HCV. Its pipeline includes BMS-663068, an HIV-1 attachment inhibitor that binds directly to HIV-1 gp120; second generation HIV-1 maturation inhibitor BMS-955176; and non-nucleoside HCV NS5B polymerase inhibitor beclabuvir ( BMS-791325). ...